The Justice Department says Schwarz Pharma Inc. will pay $22 million for allegedly failing to disclose that two of its products did not qualify for federal health care coverage.
United Therapeutics Corp.'s first-quarter profit increased 43 percent after the Food and Drug Administration approved two of its blood pressure drugs.
Drugmaker Bristol-Myers Squibb Co. reported double-digit jumps in first-quarter sales and profit, beating Wall Street expectations, but it lowered its 2010 profit forecast by a nickel due to the impact of the health care overhaul.
Two subsidiaries of pharmaceutical giant Johnson & Johnson have agreed to pay more than $81 million stemming from allegedly illegal promotion of the epilepsy drug Topamax for psychiatric uses, the Justice Department announced.
Three top drugmakers have posted healthy increases in first-quarter sales and profits, with strong sales of key drugs buoying Bristol-Myers Squibb Co., AstraZeneca LP and Sanofi-Aventis SA.
The next time Stephen Quake is prescribed a drug, he says he won't worry about having a bad reaction. The Stanford University professor will simply consult his genome to see if there are any warning signs in his DNA.
Illumina, Inc. announced shipment of HiScanSQ, the first instrument to integrate microarray analysis and next-generation sequencing in a modular design that can evolve with changing research needs.
Almac will be attending BIO 2010, the annual Bio Industry Association convention, at which it will announce the extension of its unique site specific PEGylation technology to cover single domain antibody fragments.
Thanks to an interdisciplinary team of researchers, scientists now have a more complete understanding of one of the human body’s most vital structures: the red blood cell.
The density of transposable (jumping) elements between sex chromosomes in primates may have important consequences for the studies of human genetic diseases, say Penn State University researchers.
EyeGate Pharma announces that they have established a research collaboration with GlaxoSmithKline (GSK) to evaluate the delivery of several GSK therapies using the EyeGate II delivery system.
Pharmacy benefits manager Medco Health Solutions Inc. said its profit grew 10 percent in the first quarter as it started doing business with several large new clients.
TxCell SA announced positive preliminary results from the ongoing Phase 1/2a clinical trial regarding OvaSave, an investigational new drug, in patients with severe and refractory Crohn’s disease.
People with a common, obesity-related liver disease that has no known treatment got a surprising benefit from vitamin E pills, researchers reported.
Sanofi-Aventis reported an 8.6 percent increase in first quarter net profit thanks to its swine flu vaccine and strong sales of diabetes treatment Lantus.